Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11069163 | 1.00 | L3MBTL3 (0.46) | L3MBTL3CYP1A2ALDH1A1L3MBTL1OPRM1 | |
| SCHEMBL17520885 | 1.00 | L3MBTL3 (0.46) | L3MBTL3CYP1A2ALDH1A1L3MBTL1OPRM1 | |
| SCHEMBL17521190 | 1.00 | L3MBTL3 (0.46) | L3MBTL3CYP1A2ALDH1A1L3MBTL1OPRM1 | |
| SCHEMBL5310242 | 1.00 | L3MBTL3 (0.46) | L3MBTL3CYP1A2ALDH1A1L3MBTL1OPRM1 | |
| SCHEMBL23491287 | 1.00 | L3MBTL3 (0.46) | L3MBTL3CYP1A2ALDH1A1L3MBTL1OPRM1 | |
| SCHEMBL24914761 | 1.00 | L3MBTL3 (0.46) | L3MBTL3CYP1A2ALDH1A1L3MBTL1OPRM1 | |
| SCHEMBL19343098 | 1.00 | L3MBTL3 (0.46) | L3MBTL3CYP1A2ALDH1A1L3MBTL1OPRM1 | |
| Hydrochloric Acid SCHEMBL11869519 | 0.98 | L3MBTL3 (0.44) | L3MBTL3CYP1A2ALDH1A1L3MBTL1OPRM1 | |
| SCHEMBL10948177 | 0.97 | L3MBTL3 (0.47) | L3MBTL3ALDH1A1L3MBTL1OPRM1OPRL1 | |
| SCHEMBL19343093 | 0.97 | L3MBTL3 (0.47) | L3MBTL3ALDH1A1L3MBTL1OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022026892-A1 | PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS | TANGO THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| CN-106744853-B | A kind of graphene/black phosphorus nanometer sheet/nitrogen containing plasma liquid composite aerogel and preparation method thereof | 深圳大学 | 2019-04-26 | — | — | CN | disclosed |
| CN-106744854-B | A kind of graphene/black phosphorus quantum dot/nitrogen containing plasma liquid composite aerogel and preparation method thereof | 深圳大学 | 2019-04-26 | — | — | CN | disclosed |
| CN-106794999-B | molecular sieve SSZ-101 | 雪佛龙美国公司 | 2018-09-04 | — | — | CN | disclosed |
| CN-106795000-B | The method for preparing zeolite SSZ-52 | 雪佛龙美国公司 | 2018-09-04 | — | — | CN | disclosed |
| CN-107416784-A | A kind of two-dimentional black phosphorus nanometer sheet and its liquid phase strip preparation method | 深圳大学 | 2017-12-01 | — | — | CN | disclosed |
| CN-106744854-A | A kind of Graphene/black phosphorus quantum dot/nitrogen containing plasma liquid composite aerogel and preparation method thereof | 深圳大学 | 2017-05-31 | — | — | CN | disclosed |
| CN-106744853-A | A kind of Graphene/black phosphorus nanometer sheet/nitrogen containing plasma liquid composite aerogel and preparation method thereof | 深圳大学 | 2017-05-31 | — | — | CN | disclosed |
| CN-106794999-A | Molecular sieve SSZ 101 | 雪佛龙美国公司 | 2017-05-31 | — | — | CN | disclosed |
| CN-106795001-A | The method for preparing zeolite SSZ 52 using the structure directing agent for calculating prediction | 雪佛龙美国公司 | 2017-05-31 | — | — | CN | disclosed |
| CN-106795000-A | The method for preparing zeolite SSZ 52 | 雪佛龙美国公司 | 2017-05-31 | — | — | CN | disclosed |
| EP-2758034-A1 | COMPOSITIONS AND METHODS FOR MOLECULAR IMAGING OF OXYGEN METABOLISM | Rockland Technimed Ltd. (US) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013043236-A1 | COMPOSITIONS AND METHODS USEFUL FOR REALTIME IN SITU PHYSIOLOGICAL MOLECULAR IMAGING OF OXYGEN METABOLISM | ROCKLAND TECHNIMED, LTD. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013044186-A1 | COMPOSITIONS AND METHODS FOR MOLECULAR IMAGING OF OXYGEN METABOLISM | ROCKLAND TECHNIMED, LTD. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-20120028979-A1 | 2-(PIPERIDIN-1-YL)-4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028979-A1 | 2-(PIPERIDIN-1-YL)-4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | TLR5, TLR2, PIR | L3MBTL3 4749/4885CYP1A2 252/4885ALDH1A1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.